                         SEQUENCE LISTING

<110>  Glycotope GmbH
 
<120>  Fusion protein constructs comprising an anti-MUC1 antibody and 
       IL-15

<130>  60 328 K

<150>  EP 18 159 449.0
<151>  2018-03-01

<150>  EP 18 194 290.5
<151>  2018-09-13

<160>  34    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H1

<400>  1

Asn Tyr Trp Met Asn 
1               5   


<210>  2
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H1

<400>  2

Asp Ala Trp Met Asp 
1               5   


<210>  3
<211>  19
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H2

<400>  3

Glu Ile Arg Leu Lys Ser Asn Asn Tyr Thr Thr His Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  4
<211>  19
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H2

<400>  4

Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  5
<211>  6
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H3

<400>  5

His Tyr Tyr Phe Asp Tyr 
1               5       


<210>  6
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR H3

<400>  6

Gly Gly Tyr Gly Phe Asp Tyr 
1               5           


<210>  7
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 heavy chain variable region

<400>  7

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 
            20                  25                  30          


Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Val Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Leu Tyr 
                85                  90                  95      


Tyr Cys Thr Arg Gly Gly Tyr Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  8
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 heavy chain variable region

<400>  8

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Thr Thr His Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Ser Leu Gln Met Asn Asn Leu Arg Val Glu Asp Thr Gly Leu Tyr 
                85                  90                  95      


Tyr Cys Thr Arg His Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  9
<211>  117
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 heavy chain variable region

<400>  9

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Arg Leu Ser Cys Val Ala Ser Gly Phe Pro Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Glu Ile Arg Leu Lys Ser Asn Asn Tyr Thr Thr His Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Arg His Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  10
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L1

<400>  10

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Phe Phe 
1               5                   10                  15      


<210>  11
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L1

<400>  11

Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210>  12
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L2

<400>  12

Gln Met Ser Asn Leu Ala Ser 
1               5           


<210>  13
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L2

<400>  13

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  14
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L3

<400>  14

Ala Gln Asn Leu Glu Leu Pro Pro Thr 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 CDR L3

<400>  15

Phe Gln Gly Ser His Val Pro Leu Thr 
1               5                   


<210>  16
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 light chain variable region

<400>  16

Asp Ile Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Leu Thr Phe Gly Asp Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


Arg 
    


<210>  17
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 light chain variable region

<400>  17

Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly 
1               5                   10                  15      


Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Ile Thr Tyr Phe Phe Trp Tyr Leu Gln Lys Pro Gly Leu Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 
                85                  90                  95      


Leu Glu Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  18
<211>  113
<212>  PRT
<213>  Artificial

<220>
<223>  anti-TA-MUC1 light chain vatiable region

<400>  18

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Asn Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Ile Thr Tyr Phe Phe Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 
                85                  90                  95      


Leu Glu Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  19
<211>  4
<212>  PRT
<213>  Artificial

<220>
<223>  epitope

<400>  19

Pro Asp Thr Arg 
1               


<210>  20
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  epitope

<400>  20

Pro Asp Thr Arg Pro 
1               5   


<210>  21
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-15

<400>  21

Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 
1               5                   10                  15      


Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 
            20                  25                  30          


Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 
        35                  40                  45              


Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 
    50                  55                  60                  


Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 
65                  70                  75                  80  


Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 
                85                  90                  95      


Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 
            100                 105                 110         


Thr Ser 
        


<210>  22
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-15Ralpha sushi domain

<400>  22

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg 
65  


<210>  23
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-H1

<400>  23

Gly Tyr Thr Phe Thr Arg 
1               5       


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-H2

<400>  24

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr 
1               5                   


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-H3

<400>  25

Tyr Tyr Asp Asp His Tyr Ala Leu Asp Tyr 
1               5                   10  


<210>  26
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 heavy chain variable region

<400>  26

Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Tyr Asp Asp His Tyr Ala Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser 
        115                 


<210>  27
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-L1

<400>  27

Arg Ala Ser Ser Ser Val Ser Tyr Met Asn 
1               5                   10  


<210>  28
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-L2

<400>  28

Asp Thr Ser Lys Val Ala Ser 
1               5           


<210>  29
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDR-L3

<400>  29

Gln Gln Trp Ser Ser Asn Pro Leu Thr 
1               5                   


<210>  30
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 light chain variable region

<400>  30

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  31
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker repeat

<400>  31

Gly Gly Gly Gly Ser 
1               5   


<210>  32
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker repeat

<400>  32

Pro Ala Pro Ala Pro 
1               5   


<210>  33
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 CDR H2


<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa is any amino acid

<400>  33

Glu Ile Arg Leu Lys Ser Asn Xaa Tyr Thr Thr His Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  34
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TA-MUC1 heavy chain variable region


<220>
<221>  VARIANT
<222>  (57)..(57)
<223>  Xaa is any amino acid

<400>  34

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Arg Leu Ser Cys Val Ala Ser Gly Phe Pro Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Glu Ile Arg Leu Lys Ser Asn Xaa Tyr Thr Thr His Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Arg His Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


